Codexis

Antheia Appoints John Nicols to Chair its Board of Directors

Retrieved on: 
Giovedì, Aprile 6, 2023
Food, CSO, Nicols, Institute of technology, Chemistry, Chemical engineering, Albemarle Corporation, Growth, R, API, Synthetic biology, Massachusetts Institute of Technology, Chair, Fine chemical, Codexis, New York University

MENLO PARK, Calif., April 6, 2023 /PRNewswire/ -- Antheia, the pharmaceutical ingredient manufacturer transforming supply chains, today announced the appointment of John Nicols to Chair its Board of Directors. Nicols joins co-founders Dr. Christina Smolke (CEO) and Dr. Kristy Hawkins (CSO), as well as Ram Shriram and Dr. Patrick Yang on the Antheia Board of Directors.

Key Points: 
  • MENLO PARK, Calif., April 6, 2023 /PRNewswire/ -- Antheia , the pharmaceutical ingredient manufacturer transforming supply chains, today announced the appointment of John Nicols to Chair its Board of Directors.
  • Nicols joins co-founders Dr. Christina Smolke (CEO) and Dr. Kristy Hawkins (CSO), as well as Ram Shriram and Dr. Patrick Yang on the Antheia Board of Directors.
  • "Antheia's work to build more resilient processes for biomanufacturing essential medicines is mission-critical and will be transformative to the pharmaceutical industry," said Nicols.
  • "We're pleased to welcome John to the Antheia Board of Directors at this important stage of our company's growth," said Dr. Christina Smolke, co-founder and CEO of Antheia.

WILLOW BIOSCIENCES ANNOUNCES CHANGES TO BOARD AND MANAGEMENT

Retrieved on: 
Martedì, Marzo 28, 2023
Precigen, Xavier University, LLP, Lead, Codexis, University, Genetic engineering, Willow Springs Distilling Company, Army Science Board, PwC, Barr Pharmaceuticals, AGM, Certified Public Accountant, CBG, Development, Amyris, Partner, Chris, TSX, Growth, CFO, Research, WLLW, Compensated emancipation, Management, Willow

Since joining Willow, Dr. Savile has led the development of the technology platform, building of the operational capabilities, and expansion of the internal portfolio and external partnerships.

Key Points: 
  • Since joining Willow, Dr. Savile has led the development of the technology platform, building of the operational capabilities, and expansion of the internal portfolio and external partnerships.
  • Prior to joining Willow, Dr. Savile worked in senior leadership roles at Intrexon Corporation, a biotechnology company, and Codexis, Inc., a protein engineering company.
  • "Chris' extensive scientific knowledge and business development experience will be invaluable to Willow in its next phase of growth," said Trevor Peters, Chairman of the Board.
  • "Willow is grateful to Dr. Seufer-Wasserthal's vision and talent," said Trevor Peters, Chairman of the Board of the Company.

Codexis Announces New Employment Inducement Grants

Retrieved on: 
Giovedì, Marzo 9, 2023
RSU, Compensated emancipation, Pharmaceutical industry, Lease, Codexis

REDWOOD CITY, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the approval of equity grants to two new employees as approved by the Compensation Committee of Codexis’s Board of Directors.

Key Points: 
  • REDWOOD CITY, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the approval of equity grants to two new employees as approved by the Compensation Committee of Codexis’s Board of Directors.
  • The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 43,403 shares of Codexis’ common stock and (ii) restricted stock units (RSUs) for 9,723 shares of Codexis common stock as inducement awards under the company’s 2022 Employee Inducement Incentive Award Plan.
  • The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The RSUs will entitle each employee to receive one share of Codexis’ common stock for each RSU that vests.

Codexis to Participate in Cowen 43rd Annual Health Care Conference

Retrieved on: 
Lunedì, Febbraio 27, 2023
Conference, Doctor of Philosophy, MBBS, Drug discovery, Pharmaceutical industry, Medical device, Codexis

REDWOOD CITY, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will participate in both a panel discussion and a fireside chat at the Cowen 43rd Annual Health Care Conference, being held March 6-8, 2023, in Boston, Massachusetts.

Key Points: 
  • REDWOOD CITY, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will participate in both a panel discussion and a fireside chat at the Cowen 43rd Annual Health Care Conference, being held March 6-8, 2023, in Boston, Massachusetts.
  • Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Codexis, will participate in a panel discussion titled, “SynBio & AI Driven Drug Discovery,” taking place on Monday, March 6, 2023, at 4:40 pm ET.
  • Dr. Dilly and other members of the management team will also participate in a fireside chat taking place on Tuesday, March 7, 2023, at 11:10 am ET.
  • Webcasts of both events will be available in the Investor Relations section of the Company’s website, http://ir.codexis.com .The panel presentation and fireside chat webcasts will be archived for 30 and 90 days, respectively, following the event.

Codexis and Nestlé Health Science Announce Interim Results from Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency

Retrieved on: 
Giovedì, Febbraio 23, 2023
Safety, Doctor of Philosophy, MBBS, Pancreatitis, Cystic fibrosis, Pancreatic cancer, Investigational New Drug, Partnership, SAD, IND, EPI, PERT, Steatorrhea, Patient, Stomach, MAD, GI, Exocrine pancreatic insufficiency, Medicine, Science, Single, SAE, Pharmacokinetics, Pharmaceutical industry, Codexis

“We are excited by the early clinical data for CDX-7108, the most advanced candidate from our partnership with Nestlé Health Science,” said Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Codexis.

Key Points: 
  • “We are excited by the early clinical data for CDX-7108, the most advanced candidate from our partnership with Nestlé Health Science,” said Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Codexis.
  • “This interim Phase 1 data suggests that CDX-7108 could be that potential new option and we are excited to move forward to a Phase 2 clinical trial.
  • Codexis and Nestlé Health Science expect to file an Investigational New Drug (IND) application for the Phase 2 study by the end of 2023.
  • The Phase 2 study is expected to be conducted over approximately 12 months, with topline data expected in 2025.

Codexis Reports Fourth Quarter and Fiscal Year 2022 Financial Results

Retrieved on: 
Giovedì, Febbraio 23, 2023
NGS, JD, Depreciation, Doctor of Philosophy, DNA, MBBS, Merck, National Center for Advancing Translational Sciences, General Administration of Press and Publication, Genomics, Metabolism, Investigational New Drug, Workforce, Partnership, IND, IEM, EPI, Terminal deoxynucleotidyl transferase, Exocrine pancreatic insufficiency, Steatorrhea, Mass meeting, Patient, R, Fabry disease, MAI, Enzyme, PKU, Probability, Synthetic biology, ROFN, Serum, Doctor of Science, Takeda Pharmaceutical Company, General counsel, Rhode Island Division of Commercial Licensing and Regulation, Administration, Roche, Cryptocurrency, Pharmaceutical industry, Fine chemical, Video game, Phenylketonuria, Takeda, Fabry, Codexis, Science

REDWOOD CITY, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided a business update.

Key Points: 
  • Total revenues for the fourth quarter 2022 were $30.4 million, an increase of 24% from $24.5 million in the fourth quarter 2021.
  • R&D revenues for the fourth quarter 2022 were $7.1 million compared to $7.5 million in the fourth quarter 2021.
  • Product gross margin for the fourth quarter 2022 was 64% compared to 60% in the fourth quarter 2021, driven by changes in sales mix.
  • Selling, General & Administrative expenses for the fourth quarter 2022 were $12.3 million, compared to $11.7 million in the fourth quarter 2021.

Codexis Announces Several Key Presentations from its Gene Therapy Programs at 19th Annual WORLDSymposium™

Retrieved on: 
Mercoledì, Febbraio 22, 2023
Tissue, Lysosome, GM1, Skin, Glycogen storage disease, MBBS, Patient, Half-life, Pain, Disease, Heart, Kaay Raav Tumhi, Partnership, ERT, Fabry disease, Abstract, CNS, Enzyme, Kidney, AAV, Serum, Fatigue, Transgene, Peripheral nervous system, Takeda Pharmaceutical Company, Protein engineering, OnDemand, DSM-IV codes, Poster, Enzyme replacement therapy, Pharmaceutical industry, Vaccine, Takeda, Fabry, Codexis

REDWOOD CITY, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today highlights several key presentations from its gene therapy programs from 19 th Annual WORLDSymposium™ , taking place from February 22-26, 2023, in Orlando, Florida.

Key Points: 
  • REDWOOD CITY, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today highlights several key presentations from its gene therapy programs from 19 th Annual WORLDSymposium™ , taking place from February 22-26, 2023, in Orlando, Florida.
  • Takeda is combining these improved transgenes with its gene therapy capabilities to develop novel product candidates for the treatment of rare genetic disorders.
  • Takeda’s poster presentation, titled, “Preventing Fabry disease progression in a symptomatic mouse model with a recombinant adeno-associated virus (rAAV) based gene therapy,” highlights its rAAV-based gene therapy candidate for the potential treatment of Fabry disease.
  • Codexis is also presenting two abstracts highlighting its gene therapy program in GM1 Gangliosidosis (GM1) at WORLDSymposium™.

Global Specialty Enzymes Market Outlook Report 2023-2027: Increasing R&D, Spreading New Infectious Diseases, Biofuel Usage, and Growing Agriculture Industry to Bolster Demand - ResearchAndMarkets.com

Retrieved on: 
Mercoledì, Febbraio 22, 2023
Biotechnology, Chemicals, Plastics, Health, Manufacturing, Protein, Quality of life, DNA, Human, BASF, Pathology, Metabolism, Coronavirus diseases, Carbohydrase, USD, Acquisition, Biomarker, Research, Radiology, Alpha, Protease, CT, X-ray, Enzyme, Growth, DSM, CHR, Environment, Metalloproteinase, Plant, Lipase, Conditional sentence, Catalysis, Nature, Investment, Infection, Animal, COVID-19, Threonine, Cysteine, BASF SE, RNA, Fine chemical, Novozymes, Codexis, Cellulase

Factors such as the rapidly increasing global population, increasing research & development, spreading new infectious diseases, increasing biofuel usage, and growing agriculture industry led to increased demand for specialty enzymes in the global market.

Key Points: 
  • Factors such as the rapidly increasing global population, increasing research & development, spreading new infectious diseases, increasing biofuel usage, and growing agriculture industry led to increased demand for specialty enzymes in the global market.
  • Globally, the demand for specialty enzymes is very high in the US, and North America dominates the global specialty enzymes market.
  • Thus, the demand for specialty enzymes in North America's pharmaceutical industry is increasing with the growing pharmaceutical industry.
  • Globally, microorganisms-based enzymes contributed 77.47%, followed by animal and plant-based enzymes in 2021 in the global specialty enzymes market.

WILLOW ANNOUNCES APPOINTMENT OF DR. JIM LALONDE TO BOARD OF DIRECTORS

Retrieved on: 
Mercoledì, Febbraio 22, 2023
DSM (company), Biocatalysis, Willow, Synthetic biology, Protein engineering, TSX, Ichneutica inscripta, Doctor of Philosophy, Health, Coronavirus Scientific Advisory Board, Food, Lalonde, AB, Growth, Chemistry, Lakehead University, Drug discovery, WLLW, Enzyme, Texas A&M University, Lead, Fine chemical, Codexis

"We are very pleased to welcome Jim to our Board," said Dr. Peter Seufer-Wasserthal, Willow's President and CEO.

Key Points: 
  • "We are very pleased to welcome Jim to our Board," said Dr. Peter Seufer-Wasserthal, Willow's President and CEO.
  • Dr. Lalonde previously served with Inscripta, a global leader in genome engineering technology, as Lead of its Microbial Digital Genome Engineering Business.
  • Prior to that, Dr. Lalonde was Senior Vice President of R&D at Codexis, Inc., a leader in protein engineering.
  • Prior to Codexis, Dr. Lalonde held leadership roles in biocatalysis and chemical development at Altus Biologics and in scientific research at Vista Chemical Company.

Codexis Announces New Employment Inducement Grants

Retrieved on: 
Mercoledì, Febbraio 15, 2023
RSU, Committee, Compensated emancipation, Pharmaceutical industry, Security (finance), Codexis

In connection with Mr. Ryali’s appointment, on February 10, 2023, the Compensation Committee of Codexis’s Board of Directors (the “Committee”) approved an equity grant to Mr. Ryali consisting of (i) a nonstatutory option to purchase up to 372,637 shares of Codexis’ common stock and (ii) restricted stock units (“RSUs”) for 111,791 shares of Codexis common stock as inducement awards under the company’s 2022 Employee Inducement Incentive Plan.

Key Points: 
  • In connection with Mr. Ryali’s appointment, on February 10, 2023, the Compensation Committee of Codexis’s Board of Directors (the “Committee”) approved an equity grant to Mr. Ryali consisting of (i) a nonstatutory option to purchase up to 372,637 shares of Codexis’ common stock and (ii) restricted stock units (“RSUs”) for 111,791 shares of Codexis common stock as inducement awards under the company’s 2022 Employee Inducement Incentive Plan.
  • The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The RSUs will entitle Mr. Ryali to receive one share of Codexis’ common stock for each RSU that vests.
  • Additionally, on February 10, 2023, the Committee granted three newly hired employees equity awards consisting of an aggregate of (i) options to purchase 78,952 shares of Codexis’ common stock and (ii) RSUs for 33,956 shares of Codexis common stock as inducement awards under the company’s 2022 Employee Inducement Incentive Plan.